Rho family GTPases control a diverse range of cellular processes, and their deregulation has been implicated in human cancer. Guanine nucleotide dissociation inhibitors (GDIs) bind and sequester GTPases in the cytosol, restricting their actions. RhoGDI2 is a member of the GDI family that acts as a metastasis suppressor in a variety of cancer types; however, very little is known about the regulation of this protein.
INTRODUCTION
The Rho family of small GTPases, the best studied of which are Rho, Rac and Cdc42, have important regulatory roles in diverse cell functions such as motility, growth and differentiation. 1, 2 Inappropriate activation of Rho GTPases is implicated in uncontrolled cell growth, invasion and metastasis of many types of cancers. 3 --5 GTPases cycle between active, guanosine triphosphate (GTP) bound states and inactive, guanosine diphosphate bound states, and the rate at which this cycle occurs is regulated by three classes of proteins: guanine nucleotide exchange factors, GTPase activating proteins and guanine nucleotide dissociation inhibitors (GDIs). 6 The RhoGDI family consists of three members (RhoGDI1, 2 and 3) that bind to Rho family GTPases, extract them from membranes, and sequester them in the cytosol, effectively maintaining them in an inactive state and disallowing effector binding. 7 GDIs are further thought to stabilize GTPases in the cytosol, enabling them to evade degradation. 8 Importantly, both RhoGDI1 and RhoGDI2 (also called LyGDI or D4GDI) have been linked to tumorigenesis and metastasis, although their precise roles in cancer vary with tumor type. 9 For instance, RhoGDI2 expression is downregulated in several cancer types including bladder, lung and lymphoma, 10 --14 but is upregulated in prostate and gastric cancer. 15, 16 Further, although they share sequence similarity, RhoGDI1 and RhoGDI2 appear to carry out different functions within the same tumor type. For example, RhoGDI2 is a potent metastasis suppressor in bladder while RhoGDI1 only weakly suppresses metastasis, 17 underscoring functional differences between RhoGDI1 and RhoGDI2.
Given the role of GDIs in cancer progression, it is important to understand how these proteins are regulated in both a normal and cancer setting. Recent identification of Tyr153 as an Src phosphorylation site on RhoGDI2 that enhances RhoGDI2 metastasis suppressor function in experimental lung metastasis assays of bladder cancer cells highlighted that phosphorylation of RhoGDI2 can modulate its metastasis suppressor function. 18 Given this, we sought to identify additional post-translational modifications of RhoGDI2, and determine whether they alter GDI function. Here, we identify Ser31 in RhoGDI2 as a site that, when phosphorylated by protein kinase C (PKC)a, inhibits RhoGDI2 function by reducing its binding to Rac1, which leads to increased Rac1 activation and decreased cytosolic sequestration.
RESULTS

RhoGDI2 is phosphorylated in cells in response to phorbol ester treatment
Previous studies showed by 32 P labeling that RhoGDI2 was phosphorylated in response to phorbol 12-myristate 13-acetate (PMA) treatment of U937 human myelomonocytic cells and Jurkat cells, 19, 20 although no further analysis was performed. Because PMA is a potent activator of the PKC family of enzymes, we decided to test whether RhoGDI2 was phosphorylated by PKC. We utilized a phospho-specific PKC substrate antibody that recognizes phosphorylated proteins with a PKC consensus sequence ([R/K]XpS[Hyd][R/K]) to assess RhoGDI2 phosphorylation in cells. We found that FLAG-RhoGDI2 expressed in 293T cells was phosphorylated at a PKC site in response to PMA in a dosedependent manner (Figure 1a ). Phosphorylation was abolished by pretreatment of the cells with the pan-PKC inhibitor GF 109203X (Figure 1a ), reinforcing that this is a PKC-mediated phosphorylation. PMA-induced phosphorylation of RhoGDI2 was maximal within 10 min and persisted at an elevated level for as long as an hour (Figure 1b) . To assess the maximum extent of this phosphorylation, immunoblotting was used to determine the fraction of total FLAG-RhoGDI2 that exhibited reduced electrophoretic mobility following PMA treatment (Figure 1c) . We found that PMA-induced phosphorylation of B45% of the RhoGDI2 protein, indicating efficient and extensive phosphorylation in response to PMA. To demonstrate that endogenous RhoGDI2 also was phosphorylated in response to PMA, endogenous RhoGDI2 was immunoprecipitated from Jurkat cell extracts and probed for phosphorylation by immunoblotting using the phospho-PKC substrate antibody. While untreated Jurkat cells had no detectable RhoGDI2 phosphorylation, PMA treatment induced PKC-mediated phosphorylation of endogenous RhoGDI2 (Figure 1d ). Serine 31 is the major site of PMA-mediated phosphorylation We employed mass spectrometry to identify sites of PMA-induced phosphorylation. FLAG-RhoGDI2 was expressed in 293T cells treated with PMA, immunoprecipitated from cell extracts and isolated by SDS --PAGE. The band corresponding to FLAG-RhoGDI2 was visualized by Coomassie staining, excised and digested. Peptides were analyzed using LC-MS/MS mass spectrometry. Sequence coverage spanned 92% of the protein (Figure 2a) , and two putative phospho-sites were identified, Ser20 and Ser31 (Figure 2b ). We made substitution mutants of both sites to alanine, S20A-and S31A-RhoGDI2, and assayed their phosphorylation by PKC in 293T cells in response to PMA treatment. Mutation of Ser31 to Ala completely abolished PMA-induced phosphorylation, while mutation of Ser20 to Ala had no effect on phosphorylation (Figure 2c ), indicating that Ser31 is the major site of PMA-induced phosphorylation in RhoGDI2. The results with wild type and S31A-RhoGDI2 were replicated in UM-UC-3 bladder cancer cells (Figure 2d ).
PKCa phosphorylates RhoGDI2
We next wanted to identify the PKC isoform/s responsible for PMAinduced Ser31 phosphorylation in RhoGDI2. As a first approach, we pretreated 293T cells with either the pan-PKC inhibitor GF 109203X or the compound Gö 6976 that preferentially inhibits the conventional type PKC isoforms (PKCa, b or g). Both compounds abolished PMA-induced phosphorylation of RhoGDI2 (Figure 3a) , indicating that one of the conventional PKCs may be responsible for RhoGDI2 phosphorylation. PKCg expression is primarily but not exclusively restricted to neurons 21 and was not detected in 293T cells, 22 so we concluded that either PKCa or PKCb likely was responsible for RhoGDI2 phosphorylation. We used a SmartPool of siRNA oligos to knockdown PKCa in UM-UC-3 bladder cells that were stably expressing FLAG-RhoGDI2. These cells were utilized because the effects of expressing RhoGDI2 in this cell type are well characterized, 17, 18 and we have found they express high levels of PKCa relative to non-tumorigenic bladder cell lines (EM Griner and D Theodorescu, unpublished observations). Knockdown of PKCa was effective based on reduction in immunoblotting intensity and did not alter expression levels of PKCb (Figure 3b ). Selective depletion of PKCa reduced PMA-induced RhoGDI2 phosphorylation by over 70% (Figure 3c ), indicating that PKCa is the predominant PKC isoform involved in PMA-mediated RhoGDI2 phosphorylation in these cells. We alternatively employed a single siRNA to knockdown PKCa and observed a similar reduction in RhoGDI2 phosphorylation (Supplementary Figure 1A) . and the resulting lysates were immunoprecipitated using IgG control antibody or anti-RhoGDI2 antibody and Protein A agarose beads. Phosphorylation of endogenous RhoGDI2 was assessed by western blot using an anti-phospho PKC substrate antibody and total RhoGDI2 was assessed using an anti-RhoGDI2 antibody. To complement these data, we utilized a plasmid encoding myristoylated PKCa (Myr-PKCa) that is targeted to membranes as a highly active form of PKCa. 23 Expression of Myr-PKCa in 293T cells increased both basal and PMA-stimulated levels of RhoGDI2 phosphorylation (Figure 3d ). Further, this enhanced phosphorylation was specific for Ser31, as the S31A-RhoGDI2 mutant was not phosphorylated in the presence of Myr-PKCa (Figure 3d ). Next, in-vitro kinase assays were performed to determine if PKCa directly phosphorylated RhoGDI2. FLAG-RhoGDI2 was immunoprecipitated from untreated 293T cells, incubated with purified recombinant PKCa in vitro, and assessed for phosphorylation of Ser31 by western blotting. Addition of recombinant PKCa to the assays led to robust phosphorylation of RhoGDI2, which was blocked entirely by the addition of the PKC inhibitor GF 109203X to the reaction (Figure 3e ). The S31A-RhoGDI2 mutant was not phosphorylated by PKCa in vitro (Figure 3e ), confirming that Ser31 was the site of PKCa-mediated phosphorylation both in vitro and in cells. Together, these data identified PKCa as the predominant PKC isoform responsible for PMA-stimulated RhoGDI2 phosphorylation at Ser31.
Phospho-mimetic S31E-RhoGDI2 has reduced binding to Rac1
The major function of GDIs is to bind to small GTPases; therefore, we sought to determine the effect of Ser31 phosphorylation on GTPase binding. As a first approach, we examined the threedimensional structure of RhoGDI2 bound to Rac2. 24 In this structure, residues 32 --52 of the N-terminal portion of RhoGDI2 form a helix-loop-helix (helical hairpin) motif that is essential for Rac binding (Figure 4a , boxed region). This motif binds to the switch I and II regions of Rac and this interaction is further strengthened by contacts formed between residues 22 and 31 of RhoGDI2 and Rac. 24 As seen in Figure 4a , the hydroxyl oxygen of Ser31 caps the first turn of the helical hairpin motif and forms two hydrogen bonds with Glu34. Addition of a negatively charged phosphate group at Ser31 would be expected to both eliminate stabilizing bonds and repel the negatively charged Glu34 in the RhoGDI2 helical hairpin and ultimately lead to decreased binding affinity for Rac.
Given our structure-based predictions, we chose to assess the ability of RhoGDI2 Ser31 mutants to bind to Rac1, the major binding partner of RhoGDI2. 18 To do this, we generated a phospho-mimetic mutant, S31E-RhoGDI2, and co-expressed it or wild-type RhoGDI2 in 293T cells with HA-tagged Rac1. Proteins were immunoprecipitated using an anti-HA antibody and the amount of FLAG-RhoGDI2 that co-immunoprecipitated with Rac1 was analyzed by immunoblotting. While WT-RhoGDI2 effectively co-immunoprecipitated with Rac1, the levels of co-precipitated S31E-RhoGDI2 were lower (Figure 4b) , suggesting that the phospho-mimetic mutant has a reduced affinity for Rac1. Interestingly, the S31A-RhoGDI2 mutant also showed slightly reduced levels of immunoprecipitation with Rac1 that was significantly different from WT, but not reduced to the same extent as that for S31E-RhoGDI2. Loss of the polar hydroxyl group of Ser31 by mutation to Ala would eliminate the two stabilizing bonds capping helix 1 and likely decrease the stability of the helical hairpin motif (Figure 4a ) at the Rac-RhoGDI2 interface. As a control, we performed the same set of experiments with S20A-and S20E-RhoGDI2. Neither the phospho-mimetic nor the non-phosphorylatable Ser20 mutants showed significant changes in Rac1 binding relative to wild type (Supplementary Figure 1B) . We concluded that phosphorylation of RhoGDI2 at Ser31 disrupts binding to Rac1.
From these data, we hypothesized that PMA treatment of cells would increase RhoGDI2 phosphorylation and therefore decrease the amount of RhoGDI2 bound to Rac1. Interestingly, we did not see a decrease in the amount of FLAG-RhoGDI2 that co-immunoprecipitated with HA-Rac1 after PMA treatment of cells ( Figure 4c ). As controls, cells expressing RhoGDI2 were treated with PMA and RhoGDI2 immunoprecipitated using anti-FLAG antibody. While robust phosphorylation of the cellular pool of RhoGDI2 was seen in response to PMA treatment, no phosphorylation was detected in the RhoGDI2 that co-immunoprecipitated with Rac1, even when similar amounts of RhoGDI2 were compared in the western blot (Figure 4c ). These results suggested that the non-phosphorylated form of RhoGDI2 preferentially binds to Rac1.
We immunoprecipitated endogenous RhoGDI2 from Jurkat cells with and without PMA stimulation. At this time point and concentration, RhoGDI2 is effectively phosphorylated in response to PMA stimulation (Figure 1d) . We assayed by western blot the amount of endogenous Rac1 co-immunoprecipitating with RhoGDI2, and found that PMA stimulation caused an B30% decrease in Rac1 levels (Figure 4d) . These results show effects of PMA stimulation on Rac1 and RhoGDI2 binding, and agree with others who have previously reported that Rac1 is activated under these conditions. 25 S31E-RhoGDI2 has decreased activity as a Rac1 GDI protein Knowing that S31E-RhoGDI2 has impaired ability to bind to Rac1, we surmised that S31E-RhoGDI2 also would be ineffective at reducing Rac1 activation. We assayed levels of activated endogenous Rac1 in 293T cells utilizing GST-Pak-Rac/Cdc42 (p21) binding domain pull-down assays. Expression of WTRhoGDI2 effectively reduced levels of activated Rac1 in cells, and the S31A-RhoGDI2 mutant behaved similarly to WT-RhoGDI2 (Figure 5a ). This is in keeping with the observation that under these conditions, RhoGDI2 exists largely in the unphosphorylated form that binds to Rac1 (Figure 4c, non-stimulated cells) . In contrast, S31E-RhoGDI2 had no effect on levels of active Rac1 compared with control cells, indicating that this mutant has diminished GDI function, most likely due to its reduced binding to Rac1 (Figure 5a) .
We also assayed for the ability of WT-RhoGDI2 and the Ser31 mutants to extract Rac1 from the membrane. While WT-RhoGDI2 effectively decreased levels of Rac1 found in the membrane fraction, the S31E-RhoGDI2 mutant failed to change Rac1 membrane distribution in comparison with control cells (Figure 5b ), further showing that S31E-RhoGDI2 has reduced binding to Rac1 and impaired GDI function. Interestingly, the S31A-RhoGDI2 mutant also did not significantly reduce Rac1 levels at the membrane, although it did trend toward reduced Rac1 in the membrane. Altogether, these data suggest that RhoGDI2 phosphorylated at Ser31 has impaired GDI function.
DISCUSSION
Here, we identify Ser31 as a phosphorylation site in RhoGDI2 that is induced by PMA treatment of cells, and we show that the conventional type PKCa is the predominant kinase involved in this phosphorylation. Comparison of the S31E-RhoGDI2 phosphomimetic mutant with wild-type RhoGDI2 revealed reduced Rac1 binding, an increase in Rac1 activation, and an inability to extract Rac1 from membranes. The results suggest PKC phosphorylation is a potential mechanism to inactivate the RhoGDI2 metastasis suppressor protein.
Structures of RhoGDI1 or RhoGDI2 bound to Rac identified two highly similar regions of RhoGDIs: a structurally stable C-terminal immunoglobulin-like domain that binds the isoprenyl tail of GTPases, and a flexible N-terminal regulatory region consisting of a helical hairpin that binds to the switch I and II regions of Rac2 and inhibits guanosine diphosphate dissociation through stabilization of Mg þ 2 binding of switch I. 24, 26, 27 The N-terminal region of the GDIs is essential for GTPase binding, as truncation of the first 41 residues disrupts protein structure and results in a loss of function. 26 Ser31 of RhoGDI2 is found in the N-terminal region of the protein and caps the first helix of the helical hairpin structure. 24 The Ser31 residue is conserved among all members of the RhoGDI family. Interestingly, the corresponding site in RhoGDI1 (Ser 34) has been identified as a substrate for conventional PKCs; however, Ser 34 RhoGDI1 phosphorylation led to a selective decrease in binding to RhoA, but not to Rac or Cdc42. 28 While these results suggest that both RhoGDI1 and RhoGDI2 are regulated by PKCs, phosphorylation does not produce identical effects on how different GDIs interact with Rho family GTPases. The mechanism through which this occurs is unclear, but may be related to the different binding affinities RhoGDI1 and RhoGDI2 have for GTPases.
Our analysis of the RhoGDI2-Rac2 complex indicates that the Ser31 hydroxyl group of RhoGDI2 is involved in two hydrogen bonds with Glu34 that form a cap at the N-terminus of helix 1 (Figure 4a ). Because Ser31 interacts with an acidic side chain, phosphorylation or substitution of Ser31 with an acidic residue would cause electrostatic repulsion in addition to the loss of the stabilizing hydrogen bonds, and would be expected to disrupt RhoGDI2 structure and decrease its interactions with Rac. Furthermore, the residues surrounding Ser31 make important contacts with Rac, 24, 26 and it is foreseeable that phosphorylation of Ser31 could also disrupt these contacts and further interfere with GTPase binding. Nuclear magnetic resonance studies of RhoGDI1 or RhoGDI2 showed that the N-terminal 60 residues of the proteins were flexible and disordered when free in solution, but became ordered and formed a helical hairpin structure upon addition of Rac. 26, 27 This model suggests that the N-terminal region of RhoGDI2 exists in an equilibrium between a disordered state and an ordered state, and that binding of RhoGDIs to a GTPase stabilizes the ordered state and the helical hairpin structure that is essential for GTPase binding. 26 From this model and our data presented here, we propose that phosphorylation of Ser31 drives RhoGDI2 toward an unstructured form and prevents binding of RhoGDI2 to a GTPase.
Results obtained with the S31A-RhoGDI2 mutant are generally consistent with our structural analysis, and our proposed model of RhoGDI2 regulation by Ser31 phosphorylation predicts the relative severity of the deficiencies caused by the amino-acid substitutions or Ser31 phosphorylation. Substitution of Ser31 to Ala would eliminate the Ser31 hydroxyl group hydrogen bonding with Glu34 and would destabilize the protein and its interactions with Rac, although not to as great of an extent as phosphorylation of Ser31 or mutation to an acidic residue. Thus, when viewed in terms of the equilibrium between an ordered and disordered state, mutation of Ser31 to Ala would slightly shift the equilibrium toward a more disordered state. This could explain the intermediate effect of S31A-RhoGDI2 on Rac1 binding (Figure 4b ). The effect of S31A-RhoGDI2 expression on Rac1 membrane distribution (Figure 5b ) also trends toward an intermediate effect between that of WT and S31E-RhoGDI2, although the effect of S31A-RhoGDI2 is not statistically significant from either WT or S31E-RhoGDI2 in this assay. On the other hand, Rac1 activation levels in the presence of S31A-RhoGDI2 are decreased to a similar extent as in samples expressing WTRhoGDI2 (Figure 5a ). While binding to Rac1 is decreased in the S31A-RhoGDI2 mutant, it does still bind to Rac1, and this seems to be enough to depress Rac1 activation levels. It stands to reason that the S31A-RhoGDI2 mutant would behave similarly to WT-RhoGDI2 in Rac1 activation assays given that WT-RhoGDI2 is largely unphosphorylated in unstimulated cells (see Figure 4c , non-stimulated cells).
Several phosphorylation sites have been identified on RhoGDI1, but only one other major phosphorylation site in RhoGDI2, Tyr153, was identified before this work. Similarly to Ser31 phosphorylation, Src-mediated phosphorylation of Tyr153 results in decreased Rac1 binding and inability of RhoGDI2 to extract Rac1 from membranes. Because Tyr153 and Ser31 are in different structural domains of RhoGDI2, we imagine that even though phosphorylation reduces Rac1 binding in each case, it probably does so via different mechanisms. Interestingly, the phospho-mimetic Y153E-RhoGDI2 mutant has enhanced metastasis suppressor function in experimental lung metastasis assays of bladder cancer cells, 18 indicating that Src phosphorylation at Tyr153 is a means of positively regulating RhoGDI2 metastasis suppressor function in bladder. The mechanisms through which this occurs are unclear, but are thought to be related to the redistribution of RhoGDI2 to membranes occurring upon Tyr153 phosphorylation. This is in contrast to Ser31 phosphorylation, which does not appear to redistribute the protein as the majority of the S31E-RhoGDI2 phospho-mimetic mutant remains in the cytosol (Figure 5b) .
Given the effect of Tyr153 on RhoGDI2 function, it is clear that phosphorylation of RhoGDI2 is an important mechanism to modulate its metastasis suppressor function. It is intriguing to speculate that PKCa-mediated Ser31 phosphorylation may also have a role in modulating RhoGDI2 metastasis suppression. Interestingly, PKCa protein levels have been shown to increase in bladder cancer with increasing tumor grade, 29 and PKCa was found to be more active in transitional cell carcinomas of bladder when compared with adjacent normal tissue. 30 Further, studies using pharmacological inhibition of conventional PKCs have shown that PKCa or b can enhance migration, invasion and cell growth of bladder cancer cells, 31, 32 altogether suggesting that PKCa may be pro-tumorigenic, although extensive work remains Beads were washed thrice with cold lysis buffer, eluted with boiling sample buffer, and the proteins subjected to SDS --PAGE and western blotting with anti-FLAG antibody (Sigma). For immunoprecipitations of endogenous RhoGDI2, Jurkat cells were lysed in lysis buffer (50 mM HEPES, 5 mM MgCl 2 , 1 mM EGTA, 0.5% Triton X-100, pH 7.1), and lysates were clarified at 100 000 g for 30 min. Lysates were incubated with RhoGDI2 antibody conjugated to Protein A agarose beads for 2 h at 4 1C, then washed thrice with lysis buffer. Mutagenesis was performed using the QuikChange site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA) as per manufacturer's instructions, using pFLAG-CMV-4-RhoGDI2 as template. Rac-GTP pull downs were performed on serum-depleted HEK 293T cells as described. 33 Western blot analysis, antibodies and subcellular fractionation
Western blot images were acquired on an Odyssey Infrared Imaging System (Licor Biosciences, Lincoln, NE, USA) using anti-phospho-(Ser) PKC Substrate Antibody and anti-E-cadherin (Cell Signaling, Danvers, MA, USA); anti-FLAG, anti-HA and anti-Vinculin (Sigma); anti-D4-GDI (RhoGDI2) (Spring Bioscience, Pleasanton, CA, USA); anti-Rac1 and anti-PKCa (Millipore, Billerica, MA, USA); anti-PKCb (Rockland, Gilbertsville, PA, USA) primary antibodies. Fractionation by ultracentrifugation was carried out as previously described. 33 Mass spectrometry FLAG-RhoGDI2 immunoprecipitated from PMA stimulated (1 mM, 10 min) HEK 293T cells was subjected to SDS polyacrylamide gel electrophoresis, Coomassie stained and excised from the gel. The gel piece was transferred to a siliconized tube and washed and destained in 200 ml 50% methanol overnight. The gel pieces were dehydrated in acetonitrile, rehydrated in 30 ml of 10 mM dithiothreitol in 0.1 M ammonium bicarbonate and reduced at room temperature for 0.5 h. The dithiothreitol solution was removed and the sample alkylated in 30 ml 50 mM iodoacetamide in 0.1 M ammonium bicarbonate at room temperature for 0.5 h. The reagent was removed and the gel pieces dehydrated in 100 ml acetonitrile. The acetonitrile was removed and the gel pieces rehydrated in 100 ml 0.1 M ammonium bicarbonate. The pieces were dehydrated in 100 ml acetonitrile, the acetonitrile removed and the pieces completely dried by vacuum centrifugation. The gel pieces were rehydrated in 20 ng/ml trypsin in 50 mM ammonium bicarbonate on ice for 10 min. Any excess enzyme solution was removed and 20 ml 50 mM ammonium bicarbonate added. The sample was digested overnight at 37 1C and the peptides formed extracted from the polyacrylamide in two 30 ml aliquots of 50% acetonitrile/5% formic acid. These extracts were combined and evaporated to 15 ml for MS analysis. The LC-MS system consisted of a Finnigan LTQ-FT mass spectrometer system (Thermo, Fremont, CA, USA) with a Protanananospray ion source interfaced to a self-packed 8 cm Â 75 mm i.d. Phenomenex Jupiter 10 mm C18 reversed-phase capillary column (Phenomenex Inc., Torrance, CA, USA). In all, 0.5 --5 ml volumes of the extract were injected and the peptides eluted from the column by an acetonitrile/0.1 M acetic acid gradient at a flow rate of 0.25 ml/min. The nanospray ion source was operated at 2.8 kV. The digest was analyzed using the double play capability of the instrument acquiring full scan mass spectra to determine peptide molecular weights and product ion spectra to determine amino-acid sequence in sequential scans. This mode of analysis produces B3000 CAD spectra of ions ranging in abundance over several orders of magnitude. Not all CAD spectra are derived from peptides. The data were analyzed by database searching using the Sequest search algorithm against RhoGDI2. Potentially modified peptides were confirmed manually.
RNA interference Double-stranded RNAs (100 nM) were transfected into UM-UC-3 cells expressing FLAG-RhoGDI2 using Oligofectamine (Invitrogen, Grand Island, NY, USA). After 24 h, cells were serum starved for 16 h, pretreated with calyculin A (25 nM, 30 min), then treated with PMA (1 mM, 10 min) and lysed. FLAG-RhoGDI2 was immunoprecipitated as described above and assessed for phosphorylation. RNA duplexes used were ON-TARGET plus Smart Pool Catalog # L-003523-00 (Dharmacon, Lafayette, CO, USA), Non-Targeting Control (CATCGCTGTAGCATCGTCT) or PKCa (AATCCTTGTCCAAGGAGGCTG).
In-vitro kinase assay
RhoGDI2 immunoprecipitated from untreated HEK 293T cells was incubated for 15 min at 30 1C with recombinant human PKCa (50 ng) (EMD) in 20 mM HEPES, 10 mM MgCl 2 , 100 mM CaCl 2 , 20 mg of phosphatidylserine vesicles, 100 nM PMA and 10 mM ATP. GF 109203X was added at 5 mM.
Structural analysis
Visual inspection and measurement of structural parameters were performed using PyMol (DeLano, W.L. 2008, The PyMOL Molecular Graphics System; DeLano Scientific, Palo Alto, CA, USA). Figure 4a was generated from PDB entry 1SD6 24 using PyMol and Photoshop (Adobe).
Statistical analysis
Images were analyzed using Image J software (NIH). Data are expressed as mean ± s.e. and analyzed using Student's t-test. A P-value of o0.05 was considered statistically significant. All results shown are representative of three independent experiments unless otherwise indicated.
